|
Price: $149.0700
$3.53 
2.425%
|
| Day's High:
| $150.8
| Week Perf:
| 6.74 %
|
| Day's Low: |
$ 145.10 |
30 Day Perf: |
15.4 % |
| Volume (M): |
2,071 |
52 Wk High: |
$ 150.80 |
| Volume (M$): |
$ 308,754 |
52 Wk Avg: |
$123.70 |
| Open: |
$146.00 |
52 Wk Low: |
$89.00 |
|
|
| Market Capitalization (Millions $) |
23,702 |
| Shares
Outstanding (Millions) |
159 |
| Employees |
9,250 |
| Revenues (TTM) (Millions $) |
4,429 |
| Net Income (TTM) (Millions $) |
-3,044 |
| Cash Flow (TTM) (Millions $) |
-633 |
| Capital Exp. (TTM) (Millions $) |
163 |
Illumina Inc
Illumina Inc. is a prominent American biotechnology company that specializes in developing and manufacturing tools for genetic analysis. Founded in 1998 and headquartered in San Diego, California, Illumina has established itself as a leader in the field of genomics, particularly known for its advancements in next-generation sequencing (NGS) technologies.
Key Products and Technologies
Illuminas flagship product line includes the Genome Analyzer, an NGS platform that allows for high-throughput DNA sequencing. The company's sequencing systems leverage proprietary chemistry and advanced software algorithms to deliver highly accurate and reliable genomic data. This capability enables researchers to investigate genetic variations and unravel complex disease pathways.
In addition to the Genome Analyzer, Illumina offers a variety of other products, including:
- Microarrays: Tools used for genotyping and gene expression profiling.
- PCR (Polymerase Chain Reaction) kits: Essential for amplifying DNA sequences in various applications.
- Software platforms: Integrated solutions for managing data generated from sequencing and analysis, facilitating better visualization and interpretation of genomic data.
Applications and Impact
Illuminas products find applications across multiple sectors, including:
- Healthcare: Enhancing diagnostics and personalized medicine by enabling genomic profiling and cancer genomics.
- Research: Providing essential tools for academic and clinical research, thereby advancing our understanding of genetic disorders and diseases.
- Agriculture: Supporting genomic studies that improve crop quality and yield through genetic analysis.
The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to pioneer new therapies and treatments for challenging health issues such as cancer, diabetes, and rare genetic diseases.
Services
Illumina also provides comprehensive sequencing and data analysis services, catering to both research applications and clinical diagnostics. This includes supporting initiatives like population genomics and large-scale health studies, which aim to uncover actionable insights from genomic data.
Commitment to Innovation
Illumina maintains a strong dedication to innovation, investing significantly in research and development to advance its technology offerings. The company has introduced numerous enhancements to its sequencing platforms, striving to lower costs and increase throughput while improving data quality.
Noteworthy Initiatives
The company has been involved in several major scientific and genomic initiatives, such as:
- The 100,000 Genomes Project in the UK, aimed at understanding rare diseases and cancer through extensive genomic sequencing.
- The All of Us Research Program in the United States, which seeks to gather health data from diverse populations to promote personalized medicine and enhance health outcomes.
Conclusion
Illumina Inc. is a cornerstone of the genomic analysis landscape, providing sophisticated technology and solutions that empower researchers and healthcare professionals. Through its continuous innovation and strategic partnerships, Illumina plays a pivotal role in advancing scientific knowledge and improving healthcare outcomes worldwide.
Company Address: 5200 Illumina Way San Diego 92122 CA
Company Phone Number: 202-4500 Stock Exchange / Ticker: NASDAQ ILMN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Illumina Inc
Illumina Inc Faces Deteriorating Business and Losses in First Quarter Earnings
San Diego-based biotechnology company, Illumina Inc (NASDAQ: ILMN), reported disappointing financial performance in the first quarter of the 2024 earnings season. The company experienced a deteriorating business, resulting in a net loss of -$126.000 million. This is a significant difference from the corresponding financial reporting period the previous year, which saw net proceeds of $3.000 million.
The company's revenue also took a hit, sinking by -1.012% to $1.08 billion. Furthermore, the loss per share stood at -$0.79, a significant decrease compared to the $0.02 per share seen in the same period last year.
|
| Personnel Announcements
Published Tue, Apr 9 2024 8:05 PM UTC
Illumina Appoints New CFO and CSO, Reaffirms Financial Guidance
San Diego-based biotechnology company, Illumina Inc (NASDAQ: ILMN), recently made significant changes to its leadership team. Ankur Dhingra has been appointed as the Chief Financial Officer (CFO), while Jakob Wedel will take on the role of Chief Strategy and Corporate Development Officer (CSO). Additionally,...
|
| Illumina Inc
Illumina Inc, a leading company in the Laboratory Analytical Instruments sector, has recently reported its fiscal results for the three months ending December 31, 2023. Despite a net loss per share of $-1.11, which was higher than the previous year's $-0.87, the company saw a 3.506% increase in revenue to $1.12 billion compared to the same period a year ago.
Many analysts were surprised by Illumina Inc's revenue gain, especially considering the overall contraction of 11.60% in the Laboratory Analytical Instruments sector. In the previous financial reporting period, the company had achieved revenue of $1.12 billion and a bottom line of $-4.77 per share.
|
| Illumina Inc
Illumina Inc, a Laboratory Analytical Instruments company, experienced a challenging third quarter in 2023, reporting a loss of $-4.77 per share. This marked an improvement from the previous year, where the loss per share was significantly higher at $-24.26.
Interestingly, while most companies in the Laboratory Analytical Instruments sector saw a decline in revenue, Illumina Inc managed to achieve a slight growth of 0.359%. The company's revenue reached $1.12 billion during the quarter, compared to $1.12 billion in the same period the previous year. However, there was a sequential decrease in revenue of -4.847% from $1.18 billion.
|
| Illumina Inc
Illumina Inc. (ILMN), a pioneer in the field of genomics research and technology, recently announced its financial results for the first quarter of 2023. Despite a slight decline in revenue, the company was able to turn a profit, marking a significant improvement over the same period in 2022.
In the first quarter of 2023, ILMN reported earnings per share (EPS) of $0.02, a significant increase from the EPS of -$0.87 reported in the prior year. The company's revenue in Q1 2023 was $1.09 billion, a decrease of -2.511% from the same period last year. However, the revenue still showed an overall increase of 0.277% from the prior reporting period, indicating that the company is on a gradual path of growth.
|
| Per Share |
Current |
| Earnings (TTM) |
-19.15 $ |
| Revenues (TTM) |
27.86 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.47 $
|
| Book Value |
9.03 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-19.15 $
|
| Revenues (TTM) |
27.86 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.47 $
|
| Book Value |
9.03 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Americas |
|
 57.55 % |
of total Revenue |
| Europe |
|
25.99 % |
of total Revenue |
| Greater China |
|
6.74 % |
of total Revenue |
| Asia-Pacific, Middle East, and Africa |
|
9.71 % |
of total Revenue |
| Total product revenue |
|
83.36 % |
of total Revenue |
| Consumables |
|
72.57 % |
of total Revenue |
| Instruments |
|
10.79 % |
of total Revenue |
| Service and other revenue |
|
16.64 % |
of total Revenue |
| Sequencing |
|
91.37 % |
of total Revenue |
| Sequencing Total product revenue |
|
75.99 % |
of total Revenue |
| Sequencing Consumables |
|
65.56 % |
of total Revenue |
| Sequencing Instruments |
|
10.43 % |
of total Revenue |
| Sequencing Service and other revenue |
|
15.38 % |
of total Revenue |
| Microarray |
|
8.63 % |
of total Revenue |
| Microarray Total product revenue |
|
7.37 % |
of total Revenue |
| Microarray Consumables |
|
7.01 % |
of total Revenue |
| Microarray Instruments |
|
0.36 % |
of total Revenue |
| Microarray Service and other revenue |
|
1.26 % |
of total Revenue |
|
|
